Advances in platinum-intercalators of DNA as antitumor agents

WANG Tianshuai; YU Junjie; ZHANG Yan; ZENG Jinjin; CUI Jingxin

doi:10.11665/j.issn.1000-5048.20190501

Journal of China Pharmaceutical University > 2019 > 50(5): 505-515. > DOI: 10.11665/j.issn.1000-5048.20190501

WANG Tianshuai, YU Junjie, ZHANG Yan, ZENG Jinjin, CUI Jingxin. Advances in platinum-intercalators of DNA as antitumor agents[J]. Journal of China Pharmaceutical University, 2019, 50(5): 505-515. DOI: 10.11665/j.issn.1000-5048.20190501

Citation:

PDF (3767 KB)

Advances in platinum-intercalators of DNA as antitumor agents

More Information

Graphical Abstract

Abstract

Abstract

Platinum antitumor drugs are widely used for clinical treatment because of their unique antitumor mechanisms, significant antitumor effects, and broad antitumor spectrum. Yet shortcomings such as toxic side effects, drug resistance and cross-resistance of platinum-based drugs have limited their further application. Platinum-intercalator conjugates possess different antitumor mechanisms from those of classic platinum drugs, and have unique advantages in overcoming the disadvantages of classic platinum antitumor drugs. The platinum-intercalator conjugates can be classified into six categories based on the different DNA-intercalator: platinum-acridine, platinum-quinoline, platinum-indole, platinum-naphthalimides, platinum-anthraquinone and platinum-based antitumor agents containing other types of intercalating groups. This article summarizes the research progress of platinum-based antitumor drugs containing DNA insertion groups in recent years.
- platinum complex,
- antitumor agent,
- DNA intercalators,
- research progress

FullText(HTML)

References (61)

References

[1]	Wheate NJ, Walker S, Craig GE, et al. The status of platinum anticancer drugs in the clinic and in clinical trials[J].Dalton Trans,2010,39(35):8113-8127.
[2]	Bai L,Gao C,Liu Q,et al.Research progress in modern structure of platinum complexes[J].Eur J Med Chem,2017,140:349-382.
[3]	Oun R,Moussa YE,Wheate NJ.Correction:the side effects of platinum-based chemotherapy drugs:a review for chemists[J].Dalton Trans,2018,47(23):7848.
[4]	Wang X,Guo Z.Targeting and delivery of platinum-based anticancer drugs[J].Chem Soc Rev,2013,42(1):202-224.
[5]	Gao C,Wang T,Chen J,et al.Recent research in antitumor mechanism of platinum-based drugs[J].J Kunming Univ Sci Technol(Nat Sci)(昆明理工大学学报自然科学版),2014,39(4):83-92.
[6]	Deo KM,Pages BJ,Ang DL,et al.Transition metal intercalators as anticancer agents-recent advances[J].Int J Mol Sci,2016,17(11):1818-1835.
[7]	Wemmer DE. Ligands recognizing the minor groove of DNA:development and applications[J].Biopolymers,1999,52(4):197-211.
[8]	Lerman LS.Acridine mutagens and DNA structure[J].J Cell Comp Physiol,1964,64(S1):1-18.
[9]	Yao L,Shen S.Research progress of DNA-intercalators[J].World Clinic Drugs(世界临床药物),2010,31(5):299-305.
[10]	Schatzschneider U.Metallointercalators and metalloinsertors:structural requirements for DNA recognition and anticancer acti-vity[J].Metal Ions Life Sci,2018,18:387-436.
[11]	Liu HK,Sadler PJ.Metal complexes as DNA intercalators[J].Acc Chem Res, 2011,44(5):349-359.
[12]	Kourková M,Sabolová D,Kristian P.A review on acridinylthioureas and its derivatives:biological and cytotoxic activity[J].J Appl Toxicol,2017,37(10):1132-1139.
[13]	Graham LA,Suryadi J,West TK,et al.Synthesis,aqueous reactivity,and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents[J].J Med Chem,2012,55(17):7817-7827.
[14]	Ma ZD,Choudhury JR,Wright MW,et al.A non-cross-linking platinum-acridine agent with potent activity in non-small cell lung cancer[J].J Med Chem,2008,51(23):7574-7580.
[15]	Nepali K,Sharma S,Sharma M,et al.Rational approaches,design strategies,structure activity relationship and mechanistic insights for anticancer hybrids[J].Eur J Med Chem,2014,77:422-487.
[16]	Choudhury JR,Rao L,Bierbach U.Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay[J].J Biol Inorg Chem,2011,16(3):373-380.
[17]	Suryadi J, Bierbach U. DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers[J].Chemistry,2012,18(41):12926-12934.
[18]	Kava HW,Galea AM,Md.Jamil F,et al.Characterising the atypical 5′-CG DNA sequence specificity of 9-aminoacridine carboxamide Pt complexes[J].J Biol Inorg Chem,2014,19(6):997-1007.
[19]	Kava HW,Murray V.CpG methylation increases the DNA binding of 9-aminoacridine carboxamide Pt analogues[J].Bioorg Med Chem,2016,24(19):4701-4710.
[20]	Kostrhunova H, Malina J, Pickard AJ, et al. Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent.Effect on DNA interactions,DNA adduct recognition and repair[J].Mol Pharm,2011,8(5):1941-1954.
[21]	Qiao X,Zeitany AE,Wright MW,et al.Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells[J].Metallomics,2012,4(7):645-652.
[22]	Choudhury JR,Bierbach U.Characterization of the bisintercalative DNA binding mode of a bifunctional platinum-acridine agent[J].Nucleic Acids Res,2005,33(17):5622-5632.
[23]	Upadhyay A,Kushwaha P,Gupta S,et al.Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents[J].Eur J Med Chem,2018,154:172-181.
[24]	Giordano A,Del FG,Johansson C,et al.Virtual fragment screening identification of a novel Quinoline-5,8-dicarboxylic acid derivative as selective JMJD3 inhibitor[J].Chem Med Chem,2018,13(12):1160-1164.
[25]	Shang XF,Morris-Natschke SL,Yang GZ,et al.Biologically active quinoline and quinazoline alkaloids part II[J].Med Res Rev,2018,38(5):1614-1660.
[26]	Jamshidi M,Yousefi R,Nabavizadeh SM,et al.Anticancer activity and DNA-binding properties of novel cationic Pt(II)complexes[J].Int J Biol Macromol,2014,66:86-96.
[27]	Zákovská A,Nováková O,Balcarová Z,et al.DNA interactions of antitumor trans-[PtCl₂(NH₃)(quinoline)][J].Eur J Biochem,1998,254(3):547-557.
[28]	Živkovi'c MD,Kljun J,Ilic-Tomic T,et al.A new class of platinum(II)complexes with phosphine ligand pta which show potent anticancer activity[J].Inorg Chem Front,2017,5(22):39-53.
[29]	Tran Thi D,Nguyen Thi Thanh C,Luc Van M,et al.Synthesis,structure and properties of two series of platinum(II)complexes containing methyleugenol or chelating methyleugenol and amine[J].Polyhedron,2015,85:104-109.
[30]	Nguyen Thi Thanh C,Truong Thi Cam M,Pham Van T,et al.Synthesis,structure and in vitro cytotoxicity of platinum(II)complexes containing eugenol and a quinolin-8-ol-derived chelator[J].Acta Crystallogr C Struct Chem,2017,73(Pt 11):1030-1037.
[31]	Nguyen Thi Thanh C,Tran Thi D,Nguyen Van H,et al.Synthesis and spectral characterization of platinum(II)complexes containing eugenol,a natural allylphenol[J].J Coord Chem,2017,70(6):1008-1019.
[32]	Nguyen Thi Thanh C,Tran Thi D,Koen R,et al.Synthesis,crystal and solution structures of platinacyclic complexes containing eugenol,the main bioactive constituent of,Ocimum sanctum,L.Oil[J].Polyhedron,2018,151:330-337.
[33]	Yuan QH,Zhou L,Gao Y.The hydrolysis mechanism of the anticancer agent trans-dichloro(ammine)(quinoline)platinum complex:a theoretical study[J].J Theor Comput Chem,2008,7(3):381-395.
[34]	Gudipati R,Anreddy RN,Manda S.Synthesis,characterization and anticancer activity of certain 3-{4-(5-mercapto-1,3,4-oxadiazole-2-yl)phenylimino}indolin-2-one derivatives[J].Saudi Pharm J,2011,19(3):153-158.
[35]	Prakash CR,Raja S.Indolinones as promising scaffold as kinase inhibitors:a review[J].Mini Rev Med Chem,2012,12(2):98-119.
[36]	Abdelraouf F,Smit E,Hasan B,et al.Sunitinib(SU11248)in patients with chemo naive extensive small cell lung cancer or who have a ‘chemosensitive’ relapse:A single-arm phase II study(EORTC-08061)[J].Eur J Cancer,2016,54:35-39.
[37]	Li YS,Peng B,Ma L,et al.Synthesis,crystal structures and antitumor activity of two platinum(II)complexes with methyl hydrazinecarbodithioate derivatives of indolin-2-one[J].Eur J Med Chem,2017,127:137-146.
[38]	Banerjee S,Kitchen JA,Bright SA,et al.Synthesis,spectroscopic and biological studies of a fluorescent Pt(II)(terpy)based 1,8-naphthalimide conjugate as a DNA targeting agent[J].Chem Commun(Camb),2013,49(76):8522-8524.
[39]	Herrera JM,Mendes F,Gama S,et al.Design and biological evaluation of new platinum(II)complexes bearing ligands with DNA-targeting ability[J].Inorg Chem,2014,53(23):12627-12634.
[40]	Chua EY,Davey GE,Chin CF,et al.Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents[J].Nucleic Acids Res,2015,43(11):5284-5296.
[41]	Navas F,Mendes F,Santos I,et al.Enhanced cytotoxicity and reactivity of a novel platinum(IV)family with DNA-targeting naphthalimide ligands[J].Inorg Chem,2017,56(11):6175-6183.
[42]	Pérez JM,López-Solera I,Montero EI,et al.Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide)complexes[J].J Med Chem, 1999,42(26):5482-5486.
[43]	Baruah H,Barry CG,Bierbach U.Platinum-intercalator conjugates:from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation[J].Curr Top Med Chem,2004,4(15):1537-1549.
[44]	Alderden RA,Mellor HR,Modok S,et al.Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug[J].Biochem Pharmacol,2006,71(8):1136-1145.
[45]	Jansen BA,Wielaard P,Kalayda GV,et al.Dinuclear platinum complexes with N,N′-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands.Part I.Synthesis,cytotoxicity,and cellular studies in A2780 human ovarian carcinoma cells[J].J Biol Inorg Chem,2004,9(4):403-413.
[46]	Domínguez-Martín A,Brandi-Blanco MDP,Matilla-Hernández A,et al.Unravelling the versatile metal binding modes of adenine:looking at the molecular recognition patterns of deaza- and aza-adenines in mixed ligand metal complexes[J].Coord Chem Rev,2013,257(19/20):2814-2838.
[47]	Žtarha P,Vano J,Trávníek Z.Platinum complexes containing adenine-based ligands:an overview of selected structural features[J].Coord Chem Rev,2017,332:1-29.
[48]	Tomé M,López C,González A,et al.Trans- and cis-2-phenylindole platinum(II)complexes as cytotoxic agents against human breast adenocarcinoma cell lines[J].J Mol Struct,2013,1048(11):88-97.
[49]	Harper BW,Aldrich-Wright JR.The synthesis,characterisation and cytotoxicity of bisintercalating(2,2′:6′,2″-terpyridine)platinum(II)complexes[J].Dalton Trans,2015,44(1):87-96.
[50]	Krauseheuer Heuer AM,Grünert R,Kühne S,et al.Studies of the mechanism of action of platinum(II)complexes with potent cytotoxicity in human cancer cells.[J].J Med Chem,2009,52(17):5474-5484.
[51]	Kostjukov VV,Khomytova NM,Hernandez SAA,et al.Calculation of the electrostatic charges and energies for intercalation of aromatic drug molecules with DNA[J].Int J Quantum Chem,2011,111(3):711-721.
[52]	Fisher DM,Fenton RR,Aldrich-Wright JR.In vivo studies of a platinum(II)metallointercalator[J].Chem Commun(Camb),2008,43:5613-5615.
[53]	Kemp S,Wheate NJ,Buck DP,et al.The effect of ancillary ligand chirality and phenanthroline functional group substitution on the cytotoxicity of platinum(II)-based metallointercalators[J].J Inorg Biochem,2007,101(7):1049-1058.
[54]	Liang BB,Huo SY,Ren YL,et al.A platinum(IV)-based metallointercalator:synthesis,cytotoxicity,and redox reactions with thiol-containing compounds[J].Transition Met Chem,2015,40(1):31-37.
[55]	Hoseini SJ,Mohamadikish M,Kamali K,et al.Organoplatinum complexes containing bis(diphenylphosphino)amine as ligand:uncommon case of N-HK…I-Pt hydrogen bonding[J].Dalton Trans,2007(17):1697-1704.
[56]	Shahsavani MB,Ahmadi S,Aseman MD,et al.Anticancer activity assessment of two novel binuclear platinum(II)complexes[J].J Photochem Photobiol B,2016,161:345-354.
[57]	Pages BJ,Garbutcheon-Singh KB,Aldrich-Wright JR.Platinum intercalators of DNA as anticancer agents[J].Eur J Inorg Chem,2017,12:1613-1624.
[58]	Pracharova J,Saltarella T,Radosova Muchova T,et al.Novel antitumor cisplatin and transplatin derivatives containing 1-methyl-7-azaindole:synthesis,characterization and cellular responses[J].J Med Chem,2015,58(2):847-859.
[59]	Albert J,Bosque R,Crespo M,et al.Neutral and ionic platinum compounds containing a cyclometallated chiral primary amine:synthesis,antitumor activity,DNA interaction and topoisomerase I-cathepsin B inhibition[J].Dalton Trans,2015,44(30):13602-13614.
[60]	Qin QP,Wang SL,Tan MX,et al.Novel tacrine platinum(II)complexes display high anticancer activity via inhibition of telomerase activity,dysfunction of mitochondria,and activation of the p53 signaling pathway[J].Eur J Med Chem,2018,158:106-122.
[61]	Naik A,Rubbiani R,Gasser G,et al.Visible-light-induced annihilation of tumor cells with platinum-porphyrin conjugates[J].Angew Chem Int Ed Engl,2014,53(27):6938-6941.

Cited By

Get Citation

PDF

XML

Article views (1199) PDF downloads (1300)

Turn off MathJax

Article Contents

Abstract

References

Advances in platinum-intercalators of DNA as antitumor agents

Abstract

References

Catalog

Export File

Citation

Format

Content